C07D 213 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members

Patents for C07D 213 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members (63,273)
11/2002
11/07/2002	WO2002064546A3 Acylated 6,7,8,9-tetrahydro-5h-benzocycloheptenyl amines and their use as pharmaceutical
11/07/2002	WO2002056827A3 Substituted felbamate derived compounds
11/07/2002	WO2002044141A3 Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
11/07/2002	WO2001036365A3 Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
11/07/2002	US20020165412 N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof
11/07/2002	US20020165398 Amino-thiophene-amido derivatives
11/07/2002	US20020165394 Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
11/07/2002	US20020165391 Novel spiro compounds
11/07/2002	US20020165368 Novel azo compounds, use in dyeing, compositions containing them and dyeing processes
11/07/2002	US20020165275 Trisubstituted carbocyclic cyclophilin binding compounds and their use
11/07/2002	US20020165264 Aminal diones as potassium channel openers
11/07/2002	US20020165255 Prostaglandin agonists such as (3-(methanesulfonylamino-methyl)-phenoxy)-acetic acid methyl ester for preventing/ restoring bone mass loss
11/07/2002	US20020165236 Such as 3-(3-(4-(4-sulfamoyl-benzylsulfamoyl-phenyl)-ureido)-benzamidine for treatment of malaria
11/07/2002	US20020165232 Substituted N, N-disubstituted cycloalkyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity
11/07/2002	US20020165231 Substituted N-heteroaryl-N-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity
11/07/2002	US20020165230 Gamma-ketoacid dipeptides as inhibitors of caspase-3
11/07/2002	US20020165226 Estrogen receptor modulators
11/07/2002	US20020165224 Use of y-hydroxybutyric acid amides in the treatment of drug addiction and in particular of alcoholism
11/07/2002	US20020165223 Eating disorders; anticholesterol agents; hypotensive agents; sleep disorders
11/07/2002	US20020165219 Novel heterocycles useful in the treatment of benign prostatic hyperplasia
11/07/2002	US20020165218 Mixture of kinase inhibitor and anticancer agents
11/07/2002	US20020165203 Enzyme inhibitors; antiinflammatory agents; rheumatic diseases; antidiabetic agents
11/07/2002	US20020165202 Antiinflammatory agents; antiproliferative agents
11/07/2002	US20020165201 Cyanoguanidine prodrugs
11/07/2002	US20020165197 Administering adenosine receptor ligand
11/07/2002	US20020165167 Bacterial polypeptide deformylase (PDF) inhibitors, N-formyl hydroxylamine derivatives
11/07/2002	US20020165087 Nucleophilic substitution; granulation; colorless
11/07/2002	US20020164577 Detection of transmembrane potentials by optical methods
11/07/2002	US20020164549 Tellurium chemical sensitizers added to the photothermographic emulsion, for example tellurium complexed with four imidazolidin-2-thione groups and two chlorine atoms
11/07/2002	DE10121652A1 Verfahren zur Herstellung von 1,3-disubstituierten 2-Nitroguanidinen A process for the preparation of 1,3-disubstituted 2-nitroguanidines
11/07/2002	CA2443625A1 Use of bisphosphonates in the treatment of bone metastasis associated with prostate cancer
11/06/2002	EP1254908A1 Preparation of a camptothecin derivative by intramolecular cyclisation
11/06/2002	EP1254905A1 4-(2-Pyridyl)piperazines having 5HT7 receptor agonist activity
11/06/2002	EP1254896A1 Cationic amphiphiles, preparation and method for transfection
11/06/2002	EP1254895A1 Nitrogenous cyclic compounds and pharmaceutical compositions containing the same
11/06/2002	EP1254883A1 Process for producing sobstituted 1,1,1-trifluoro-3-butene-2-ones
11/06/2002	EP1254159A2 Process for the preparation of acetyl-amidiniophenylalanyl-cyclohexylglycyl-pyridinioalaninamides
11/06/2002	EP1254136A1 FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF
11/06/2002	EP1254117A1 Non-symmetrical ligands and catalyst systems thereof for ehtylene oligomerisation to linear alpha olefins
11/06/2002	EP1254116A1 Alpha v integrin receptor antagonists
11/06/2002	EP1254114A2 Melanocortin receptor agonists and antagonists
11/06/2002	EP1254101A1 Propionic acid derivatives and their use in the treatment of diabetes and obesity
11/06/2002	EP1253922A2 Statin-type bone growth stimulators
11/06/2002	EP1253916A1 Method of treating vaginal dryness with nicotinic acetylcholine receptor agonists
11/06/2002	EP1123303B1 Polymerisation catalyst
11/06/2002	EP1042292B1 Method for producing isoureas
11/06/2002	EP1031570B1 Immuno-modulator exhibiting anti-microbial and anti-mycobacterial activities, method for producing the same and pharmaceutical preparation for treating mycobacterioses as well as lung chronic and non specific conditions, sexually transmitted diseases and the resulting immuno-deficiency
11/06/2002	EP0758335B1 Preparation of a camptothecin derivative by intramolecular cyclisation
11/06/2002	EP0630264B1 Ligands for improving metal chelate formation kinetics
11/06/2002	CN1378542A FAB I inhibitors
11/06/2002	CN1378534A Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of coagulation cascade
11/06/2002	CN1378528A Use of carbonylamino derivatives against CNS disorders
11/06/2002	CN1378527A Biaryl ether derivatives useful as monoamine reuptake inhibitors
11/06/2002	CN1378450A Novel class of cytodifferentiating agents and histone deactylase inhibitors, and methods of use thereof
11/06/2002	CN1378449A Iron chelators and use thereof
11/06/2002	CN1378448A Torsemide polymorphs
11/06/2002	CN1378446A Method of inhibiting amyloid protein aggregation and imaging amyloid deposits
11/06/2002	CN1377880A Compound for curing vascular complication, its preparing method and treating use
11/05/2002	WO2001085673A1 Phenyl-substituted 2-enamino-keto nitriles
11/05/2002	US6476267 Process for producing aromatic primary amine by low-pressure
11/05/2002	US6476264 N-(4-carbamimidoyl-phenyl)-glycine derivatives
11/05/2002	US6476229 Processes for the manufacturing of 3-hydroxy-N,1,6-trialkyl-4-oxo-1,4-dihydropyridine-2-carboxamide
11/05/2002	US6476075 Use of substituted N, N-bis-benzyl aminoalcohol compounds inhibiting cholesteryl ester transfer protein activity
11/05/2002	US6476063 Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith
11/05/2002	US6476057 Use of substituted N, N-disubstituted cycloalkyl aminoalcohol compounds for inhibiting cholesteryl ester transfer protein activity
11/05/2002	US6476056 Antiinflammatory agents, psychological disorders
11/05/2002	US6476027 N-hydroxy 4-sulfonyl butanamide compounds
11/05/2002	US6476026 Compounds and compositions as protease inhibitors
11/05/2002	CA2408209A1 Phenyl-substituted 2-enamino-keto nitriles
11/05/2002	CA2038379C Trifluoromethyl mercaptan and mercaptoacyl derivatives and method of using same
11/05/2002	CA2038029C 1-alkyl-, 1-alkenyl- and 1-alkynylaryl-2-amino-1,3-propanediols and related compounds, a process and intermediates for their preparation and theeir use as medicaments
11/02/2002	CA2384344A1 4-(2-pyridyl)piperizines having 5ht7 receptor agonist activity
10/2002
10/31/2002	WO2002085859A1 HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS
10/31/2002	WO2002085858A1 Process for producing purified piperidine derivative
10/31/2002	WO2002085857A2 Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
10/31/2002	WO2002085855A1 2-iminopyrrolidine derivatives
10/31/2002	WO2002085850A1 Cyclic amidine derivative
10/31/2002	WO2002085838A1 Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds
10/31/2002	WO2002085822A1 Compound for organic el element and organic el element
10/31/2002	WO2002085516A1 Complex catalyst, process for producing the complex catalyst, and process for producing alcohol derivative with the complex catalyst
10/31/2002	WO2002085458A2 Use of nk-1 receptor antagonists against benign prostatic hyperplasia
10/31/2002	WO2001070675A3 Inhibitors of histone deacetylase
10/31/2002	US20020161237 (Z)-2-((2-bromo-4-(((3-hydroxybenzyl)amino)carbonyl)benzoyl) -amino)pent-2-enoic acid, for example; useful for treating psoriasis
10/31/2002	US20020161235 Compounds containing sulfhydryl, disulfide, or group(s) capable of being converted in-vivo to a sulfhydryl group, and at least one nitrate group; use as substitutes for existing tolerance-inducing nitric oxide donors
10/31/2002	US20020161234 Forming a diastereoselective epoxide from a chiral alpha-amino aldehyde
10/31/2002	US20020161227 By reacting a phosphazenium compound with Q as counteranion with a halogenated aromatic compound to substitute at least one halogen atom with Q
10/31/2002	US20020161053 Inflammatory cytokine production inhibitors, matrix metalloprotease production inhibitors, inflammatory cell adhesion molecules incidence inhibitors, antiinflammatory agents
10/31/2002	US20020161050 Benzene butyric acids and their derivatives as inhibitors of matrix metalloproteinases
10/31/2002	US20020161027 2-Methylheptylisonicotinate and process for production thereof
10/31/2002	US20020161011 Potassium channel inhibitors
10/31/2002	US20020161005 Nitrogen heterocycle compounds
10/31/2002	US20020161000 Treating diseases resulting from tissue breakdown such as heart disease, multiple sclerosis, osteo- and rheumatoid arthritis, atherosclerosis, and osteoporosis
10/31/2002	US20020160994 The beta-hydroxy lactone, such as -(+)-5-ethyl-9,10-difluoro-5-hydroxy-4,5,13,15-tetrahydro-1H,3H -oxepino(3',4':6,7)indolizino(1,2-b)quinoline-3,15-dione
10/31/2002	US20020160988 Compounds co-inducing cholinergic up-regulation and inflammation down-regulation and uses thereof
10/31/2002	US20020160968 Inhibitor of niacinamide phosphoribosyl transferase (NAPRT)
10/31/2002	US20020159973 Administering to the patient at least one statin (HMG-Coa-reductase inhibitor) in an amount effective to modulate MHC class II (Major Histocompability complex) or CD/40(antigen) expression in the patient
10/31/2002	US20020158227 Electrooptical liquid crystal system
10/31/2002	US20020157939 Subjecting a polyhydric alcohol compound having protected hydroxy group(s) to microwave irradiation in presence of basic compound or acid to deprotect the protecting groups of hydroxy group of polyhydric alcohol compound
10/31/2002	US20020157192 4-amino-2-(1-aryloxy-ethyl)phenol compound
10/31/2002	DE10120819A1 Preparation of 4-haloalkyl-nicotinonitrile, useful as a pesticide intermediate, comprises reacting 3-amino-1-haloalkyl-2-propenone with nitrile and cyclizing the novel 3-oxo-haloalkenylamino-substituted nitrile intermediate

1 ... 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 ... 633